{
  "key_points": [
    "Phase 3 clinical trial results show Novavax vaccine (NVX-CoV2373) has 90.4% efficacy in preventing symptomatic COVID-19.",
    "The vaccine demonstrated 100% protection against moderate and severe COVID-19 disease.",
    "NVX-CoV2373 showed 91.0% efficacy in high-risk individuals, including those 65 or older, or under 65 with certain comorbidities.",
    "Most common side effects included mild-to-moderate injection site pain, fatigue, headache, and muscle pain, lasting less than two days.",
    "The PREVENT-19 trial, funded by BARDA and NIAID, enrolled 29,960 volunteers in the U.S. and Mexico.",
    "The trial used a 2:1 ratio for vaccine to placebo distribution. Study blind ensured participants and investigators did not know who received the vaccine.",
    "Study results based on 77 symptomatic COVID-19 cases observed, with 63 in the placebo group and 14 in the vaccine group.",
    "NVX-CoV2373 uses recombinant protein nanoparticle technology and includes an adjuvant to enhance immune response.",
    "In addition to adults, May 2021 saw PREVENT-19 expand to include adolescents aged 12-17.",
    "The COVID-19 Prevention Network (CoVPN) and various health organizations are involved in facilitating and overseeing the trial."
  ],
  "spokespersons": [],
  "article_type": "general reporting",
  "dateline": "",
  "audience": "general public",
  "stance": "neutral"
}